Uses
INIDCATIONS AND USAGE: Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Source: US FDA prescribing information
Fixed-dose combination
Hydrocortisone and Pramoxine is a fixed-dose combination medicine indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It is available as cream, lotion and foam for topical use. MedsAcross supplies Hydrocortisone and Pramoxine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
INIDCATIONS AND USAGE: Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Source: US FDA prescribing information
Topical corticosteroids are generally applied to the affected area as a thin film three to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Source: US FDA prescribing information
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Source: US FDA prescribing information
General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area and under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free Cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Source: US FDA prescribing information
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Itching Irritation Dryness Folliculitis Hypertrichosis Acneiform eruptions Hypopigmentation Perioral dermatitis Allergic contact dermatitis Maceration of the skin Secondary infection Skin atrophy Striae Miliaria
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
9 presentations of Hydrocortisone and Pramoxine, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Hydrocortisone and Pramoxine 1 g/1 g per 100 g creamTopicalGeneric name | Hydrocortisone and Pramoxine | — | US FDA | Available on request |
| Analpram HC 25 mg/10 mg per mL lotionTopical | Hydrocortisone and Pramoxine | Legacy Pharma | US FDA | Available on request |
| Pramosone 10 mg/10 mg per mL lotionTopical | Hydrocortisone and Pramoxine | Legacy Pharma | US FDA | Available on request |
| Analpram HC 25 mg/10 mg per g creamTopical | Hydrocortisone and Pramoxine | Legacy Pharma | US FDA | Available on request |
| Pramosone 25 mg/10 mg per mL lotionTopical | Hydrocortisone and Pramoxine | Legacy Pharma | US FDA | Available on request |
| Pramosone Cream 10 mg/10 mg per g creamTopical | Hydrocortisone and Pramoxine | Legacy Pharma | US FDA | Available on request |
| Analpram HC 10 mg/10 mg per g creamTopical | Hydrocortisone and Pramoxine | Legacy Pharma | US FDA | Available on request |
| Epifoam 100 mg/100 mg per 10 g foamTopical | Hydrocortisone and Pramoxine | Viatris Specialty | US FDA | Available on request |
| Proctofoam HC 100 mg/100 mg per 10 g foamTopical | Hydrocortisone and Pramoxine | Viatris Specialty | US FDA | Available on request |
5 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | Approved | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 9 presentations of Hydrocortisone and Pramoxine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 5 brand names for Hydrocortisone and Pramoxine, including Analpram HC, Epifoam, Pramosone, Pramosone Cream, Proctofoam HC.
No listed presentation of Hydrocortisone and Pramoxine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.